Actinogen Medical Limited (ACW.AX)
AUD 0.03
(-6.9%)
AUD 0.03
(-6.9%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 9.93 Million AUD | 103.18% |
| 2023 | 4.88 Million AUD | 34.28% |
| 2022 | 3.64 Million AUD | 83.47% |
| 2021 | 1.98 Million AUD | -43.58% |
| 2020 | 3.51 Million AUD | -27.69% |
| 2019 | 4.86 Million AUD | 47.32% |
| 2018 | 3.3 Million AUD | 133.19% |
| 2017 | 1.41 Million AUD | -64.19% |
| 2016 | 3.95 Million AUD | 2476.4% |
| 2015 | 153.42 Thousand AUD | -15.33% |
| 2014 | 181.2 Thousand AUD | 5741.52% |
| 2013 | 3102.00 AUD | -93.98% |
| 2012 | 51.56 Thousand AUD | -45.41% |
| 2011 | 94.45 Thousand AUD | 1.78% |
| 2010 | 92.8 Thousand AUD | -27.57% |
| 2009 | 128.12 Thousand AUD | -17.8% |
| 2008 | 155.87 Thousand AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 FY | - AUD | -100.0% |
| 2024 Q2 | 909.03 Thousand AUD | 0.0% |
| 2024 Q4 | 9.02 Million AUD | 0.0% |
| 2023 Q2 | 1 Million AUD | 0.0% |
| 2023 FY | 4.88 Million AUD | 34.28% |
| 2023 Q4 | 3.88 Million AUD | 0.0% |
| 2022 Q2 | - AUD | 0.0% |
| 2022 FY | 3.64 Million AUD | 83.47% |
| 2022 Q4 | 3.64 Million AUD | 0.0% |
| 2021 Q4 | 1.93 Million AUD | 0.0% |
| 2021 Q2 | 50 Thousand AUD | 0.0% |
| 2021 FY | 1.98 Million AUD | -43.58% |
| 2020 Q4 | 2.77 Million AUD | 0.0% |
| 2020 FY | 3.51 Million AUD | -27.69% |
| 2020 Q2 | 739.06 Thousand AUD | 0.0% |
| 2019 Q4 | 4.78 Million AUD | 0.0% |
| 2019 FY | 4.86 Million AUD | 47.32% |
| 2019 Q2 | 79.82 Thousand AUD | 0.0% |
| 2018 Q2 | 219.11 Thousand AUD | 0.0% |
| 2018 FY | 3.3 Million AUD | 133.19% |
| 2018 Q4 | 3.08 Million AUD | 0.0% |
| 2017 Q2 | 79.98 Thousand AUD | 0.0% |
| 2017 FY | 1.41 Million AUD | -64.19% |
| 2017 Q4 | 1.33 Million AUD | 0.0% |
| 2016 Q2 | 1.41 Million AUD | 0.0% |
| 2016 Q4 | 2.54 Million AUD | 0.0% |
| 2016 FY | 3.95 Million AUD | 2476.4% |
| 2015 Q4 | 31.83 Thousand AUD | 0.0% |
| 2015 FY | 153.42 Thousand AUD | -15.33% |
| 2015 Q2 | 121.59 Thousand AUD | 0.0% |
| 2014 FY | 181.2 Thousand AUD | 5741.52% |
| 2014 Q4 | 14.14 Thousand AUD | 0.0% |
| 2014 Q2 | 167.06 Thousand AUD | 0.0% |
| 2013 FY | 3102.00 AUD | -93.98% |
| 2013 Q4 | 5740.00 AUD | 640.17% |
| 2013 Q3 | 775.50 AUD | -99.73% |
| 2013 Q2 | 290.27 Thousand AUD | 2151.92% |
| 2013 Q1 | 12.89 Thousand AUD | 0.0% |
| 2012 Q4 | 12.89 Thousand AUD | 0.0% |
| 2012 Q1 | 14.7 Thousand AUD | 0.0% |
| 2012 Q2 | 12.89 Thousand AUD | -12.34% |
| 2012 FY | 51.56 Thousand AUD | -45.41% |
| 2012 Q3 | 12.89 Thousand AUD | 0.0% |
| 2011 Q3 | 14.7 Thousand AUD | 0.0% |
| 2011 FY | 94.45 Thousand AUD | 1.78% |
| 2011 Q4 | 14.7 Thousand AUD | 0.0% |
| 2011 Q2 | 14.7 Thousand AUD | 21.51% |
| 2011 Q1 | 12.1 Thousand AUD | 0.0% |
| 2010 Q1 | 6397.25 AUD | 0.0% |
| 2010 FY | 92.8 Thousand AUD | -27.57% |
| 2010 Q4 | 12.1 Thousand AUD | 0.0% |
| 2010 Q3 | 12.1 Thousand AUD | 0.0% |
| 2010 Q2 | 12.1 Thousand AUD | 89.18% |
| 2009 FY | 128.12 Thousand AUD | -17.8% |
| 2009 Q1 | 3409.75 AUD | 0.0% |
| 2009 Q2 | 6397.25 AUD | 87.62% |
| 2009 Q3 | 6397.25 AUD | 0.0% |
| 2009 Q4 | 6397.25 AUD | 0.0% |
| 2008 FY | 155.87 Thousand AUD | 0.0% |
| 2008 Q4 | 3409.75 AUD | 0.0% |
| 2008 Q3 | 3409.75 AUD | 0.0% |
| 2008 Q2 | 3409.75 AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AdAlta Limited | 1.73 Million AUD | -471.499% |
| Acrux Limited | 5.09 Million AUD | -95.08% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -1550.245% |
| BTC Health Limited | 16.36 Thousand AUD | -60606.015% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | -33.172% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 13.689% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 88.737% |
| Biome Australia Limited | 13 Million AUD | 23.656% |
| Hexima Limited | - AUD | -Infinity% |
| Immutep Limited | 3.5 Million AUD | -183.294% |
| Memphasys Limited | 60 Thousand AUD | -16452.507% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 95.718% |
| Noxopharm Limited | 2.4 Million AUD | -313.765% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -167.525% |
| Race Oncology Limited | 4 Million AUD | -148.072% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -3219.042% |
| Starpharma Holdings Limited | 8.28 Million AUD | -19.815% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -6423.584% |
| Biotron Limited | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 4.01 Million AUD | -147.096% |
| CSL Limited | 22.41 Billion AUD | 99.956% |
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 85.053% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -54111.266% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -10359.5% |
| Patrys Limited | 1.39 Million AUD | -612.363% |
| Orthocell Limited | 5.31 Million AUD | -86.845% |
| Imugene Limited | - AUD | -Infinity% |
| PYC Therapeutics Limited | 22.05 Million AUD | 54.978% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -1013.219% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -328.888% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -58320.612% |
| Nanollose Limited | 12.5 Thousand AUD | -79345.676% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -719.258% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 4.45 Million AUD | -123.042% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -693.52% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 98.0% |
| Dimerix Limited | 583.47 Thousand AUD | -1602.121% |
| PharmAust Limited | - AUD | -Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | -2057.161% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -14993.471% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | -1997.241% |
| Immuron Limited | 4.9 Million AUD | -102.565% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -282.284% |